# Cardiology Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Josephine Baker (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML049-SYN-TD
- Date: 1969-04-28
- Fictional facility: St. Posthumous Health Center
- Fictional author: Laurent Mbeki-Fontaine, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Requested by: Colette Ashby-Nwosu, MD

## Reason for consultation

Breathlessness and tiredness three weeks after a non-ST-elevation myocardial infarction treated with a drug-eluting stent to the right coronary artery, in a 62-year-old woman. Please assess the cause of the breathlessness and her heart function, review her antiplatelet therapy and other medicines, and advise on cardiac rehabilitation and a return to performing on stage. **S**

## History

Ms. Baker, a 62-year-old singer and dancer, is seen at the request of Dr. Ashby-Nwosu five weeks after a non-ST-elevation myocardial infarction treated with a drug-eluting stent to the right coronary artery. She waited until the morning to go to hospital, thinking the pressure in her chest was the strain of losing her home. Since discharge she has had episodes of air hunger, a sudden need to take a deep breath, often while sitting or talking, beginning two or three days after leaving the hospital; they do not build with effort and come with no chest pressure, palpitations, orthopnea, cough or ankle swelling. Two cardiac rehabilitation sessions have not been limited by breath. She takes all her medicines and has not needed nitroglycerin. She has never smoked. She gave a clear account and asked to understand each choice. **S**

## Examination

| System | Finding |
|---|---|
| General | Well; talking in full sentences; blood pressure 136/82, pulse 62; oxygen saturation 98% on room air |
| Neck | Jugular venous pressure not raised |
| Cardiovascular | Regular rhythm; normal heart sounds; no murmur or gallop; right radial access site healed |
| Respiratory | Clear; no crackles or wheeze |
| Extremities | No edema |

BP 136/82 mmHg; pulse 62 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 59.6 kg; BMI 21.1 kg/m². All vital signs are synthetic.

## Data reviewed

Dr. Ashby-Nwosu's intake note and the hospital discharge summary: non-ST-elevation myocardial infarction, 90% mid right coronary artery stenosis with one drug-eluting stent, mild disease elsewhere, LDL 146 mg/dL. ECG at intake: sinus rhythm, small Q waves in II, III and aVF, no acute change. Echocardiogram this morning: ejection fraction 52%, hypokinesis of the basal and mid inferior wall, normal right ventricle, normal estimated filling pressures, no thrombus, normal valves. Intake laboratory tests: hemoglobin 12.2 g/dL, platelets 264, creatinine 0.82 mg/dL (eGFR 81), potassium 4.4 mmol/L, LDL 84 mg/dL, ALT 24 U/L, hemoglobin A1c 5.6%. Lipoprotein(a) 172 nmol/L. Home blood pressure average 136/82. Lipoprotein(a): 172 nmol/L (high); LVEF by echocardiogram: 52%. All results are synthetic.

## Assessment

1. **Cause of the breathlessness** (T45.525A). Ticagrelor-related breathlessness, with some deconditioning. The pattern is typical: air hunger at rest beginning within days of the start, without effort-related chest symptoms, with a normal oxygen saturation, clear lungs, normal filling pressures and no anemia. It is not a sign of heart damage or of a blocked stent, but it is distressing and leads some patients to stop their medicine. There is no sign of heart failure or of ongoing ischemia. **S**
2. **Heart function and further testing** (I25.10). The ejection fraction of 52% with inferior hypokinesis matches the infarct in the right coronary territory; function is at the lower limit of normal. No further imaging or stress testing is needed now. Repeat the echocardiogram only if her symptoms change. **S**
3. **Antiplatelet therapy** (I25.10). Ticagrelor is preferred over clopidogrel after an acute coronary syndrome, but changing to clopidogrel is appropriate when ticagrelor causes breathlessness that affects adherence. Change with a 600 mg loading dose of clopidogrel 24 hours after the last ticagrelor dose, then 75 mg daily, without a gap. Her bleeding risk is not high, so dual antiplatelet therapy should continue for twelve months from the infarction, then aspirin 81 mg alone. **S**
4. **Beta-blocker, ACE inhibitor and targets** (I10). Metoprolol succinate is appropriate for the first year after the infarction and, because she has high blood pressure, beyond it. Lisinopril is indicated for high blood pressure; raise it to 10 mg for a target below 130/80 mmHg, with potassium and creatinine one to two weeks later. LDL goal below 70 mg/dL with at least a 50% fall; her lipoprotein(a) of 172 nmol/L is an inherited risk-enhancing factor that statins do not lower, so reaching the LDL goal matters more, and ezetimibe should be added if LDL stays at 70 mg/dL or higher. **S**
5. **Return to the stage**. She can begin light dance practice within the rehabilitation program now. Before full performances, which can demand 6 to 9 METs, a symptom-limited exercise test at about twelve weeks, on her usual medicines, will set her exercise prescription and show whether she can perform safely. **S**
6. **Women's risk factors** (Z90.710). A hysterectomy in her thirties, and a possible early menopause if ovarian function was lost, add to her risk and are recorded as risk-enhancing factors. Hormone therapy is not used to prevent heart disease. Women are less often given full secondary prevention and cardiac rehabilitation after a heart attack, and more often have breathlessness, tiredness or other symptoms besides chest pain; her plan should be complete, and her account of her symptoms taken seriously. Screening for depression, which is common after a heart attack and worsens outcomes, is appropriate. **S**

## Recommendations

1. Stop ticagrelor; start clopidogrel 600 mg loading dose 24 hours after the last ticagrelor dose, then 75 mg daily.
2. Continue aspirin 81 mg; dual antiplatelet therapy for twelve months from the infarction, then aspirin 81 mg alone; never interrupt it without speaking to cardiology, and manage minor bleeding without stopping it.
3. Continue atorvastatin 80 mg; lipid panel four to eight weeks after the start; add ezetimibe if LDL is 70 mg/dL or higher.
4. Continue metoprolol succinate 25 mg; raise lisinopril to 10 mg daily; potassium and creatinine in one to two weeks; target below 130/80 mmHg.
5. Complete all 36 sessions of cardiac rehabilitation, with light dance practice there.
6. Symptom-limited exercise test at about twelve weeks before a return to full performances.
7. No repeat echocardiogram, stress imaging or angiography unless symptoms change.
8. Repeat the PHQ-9 at about twelve weeks; use the rehabilitation program's psychologist.
9. Influenza, COVID-19, pneumococcal and RSV vaccination as due.

## Strengths and supports

- Engagement in care and meaningful activity **S**

## Communication

Discussed with Dr. Ashby-Nwosu, who saw her the same day. The cause of the breathlessness, the change of antiplatelet medicine and the reasons for each other medicine were explained to Ms. Baker, who agreed to the change to clopidogrel and the higher dose of lisinopril. **S**

## Follow-up

Dr. Ashby-Nwosu continues her care and will send the exercise test result. Cardiology review before clopidogrel is stopped at twelve months, or sooner for chest pain, worsening breathlessness or bleeding. **S**

## Guideline basis

- 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023), American Heart Association and American College of Cardiology (Circulation 2023;148(9):e9-e119)
- 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes (2025), American College of Cardiology and American Heart Association (Circulation 2025;151(13):e771-e862)
- Acute Myocardial Infarction in Women: A Scientific Statement From the American Heart Association (2016), American Heart Association (Circulation 2016;133(9):916-947)
- Depression and Coronary Heart Disease: Recommendations for Screening, Referral, and Treatment: A Science Advisory From the American Heart Association (2008), American Heart Association (Circulation 2008;118(17):1768-1775)
- Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association (2020), American Heart Association (Circulation 2020;142(25):e506-e532)
- CMID: Clinical Monitoring Intelligence Database, ischemic heart disease and acute myocardial infarction monographs (2026), Aether Forge
